Adeona Pharmaceuticals, Inc. ("Adeona") AMEX: AEN is a development-stage company from the pharmaceutical industry, working on the diagnosis, prevention and treatment of autoimmune and central nervous system diseases. The company's corporate strategy is to establish proprietary, clinical-stage drug candidates that have demonstrated clinical efficacy for the treatment of unmet medical diseases. The products focus on developing treatments for rheumatoid arthritis (RA), multiple sclerosis (MS), dry age-related macular degeneration (AMD) and fibromyalgia.
read more
Around two weeks after the announcement that Jeff Lucero Riley, M.B.A. was joining its board of directors, Adeona Pharmaceuticals (AMEX:AEN) shares mark a fourth jump in price for the last three months.read more
VRUS, Pharmasset, Inc.
** Gilead Sciences, Inc. and VRUS reported that the companies have signed a definitive agreement under which Gilead will acquire VRUS for $137 per share in cash. The transaction values VRUS at approximately $11 billion
VRUS is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. VRUS’ primary focus is the development read more
VRUS, Pharmasset, Inc.
** Gilead Sciences, Inc. and VRUS reported that the companies have signed a definitive agreement under which Gilead will acquire VRUS for $137 per share in cash. The transaction values VRUS at approximately $11 billion
VRUS is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. VRUS’ primary focus read more
VRUS, Pharmasset, Inc.
** Gilead Sciences, Inc. and VRUS reported that the companies have signed a definitive agreement under which Gilead will acquire VRUS for $137 per share in cash. The transaction values VRUS at approximately $11 billion
VRUS is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. VRUS’ primary focus read more
someone replies to your post?